Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 윤채옥 | - |
dc.date.accessioned | 2020-09-23T01:20:30Z | - |
dc.date.available | 2020-09-23T01:20:30Z | - |
dc.date.issued | 2019-09 | - |
dc.identifier.citation | CANCER RESEARCH, v. 79, no. 17, Page. 4503-4514 | en_US |
dc.identifier.issn | 0008-5472 | - |
dc.identifier.issn | 1538-7445 | - |
dc.identifier.uri | https://cancerres.aacrjournals.org/content/79/17/4503 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/154072 | - |
dc.description.abstract | Oncolytic virotherapy is a promising alternative to conventional treatment, yet systemic delivery of these viruses to tumors remains a major challenge. In this regard, mesenchymal stem cells (MSC) with well-established tumor-homing property could serve as a promising systemic delivery tool. We showed that MSCs could be effectively infected by hepatocellular carcinoma (HCC)-targeted oncolytic adenovirus (HCC-oAd) through modification of the virus' fiber domain and that the virus replicated efficiently in the cell carrier. HCC-targeting oAd loaded in MSCs (HCC-oAd/MSC) effectively lysed HCC cells in vitro under both normoxic and hypoxic conditions as a result of the hypoxia responsiveness of HCC-oAd. Importantly, systemically administered HCC-oAd/MSC, which were initially infected with a low viral dose, homed to HCC tumors and resulted in a high level of virion accumulation in the tumors, ultimately leading to potent tumor growth inhibition. Furthermore, viral dose reduction and tumor localization of HCC-oAd/MSC prevented the induction of hepatotoxicity by attenuating HCC-oAd hepatic accumulation. Taken together, these results demonstrate that MSC-mediated systemic delivery of oAd is a promising strategy for achieving synergistic antitumor efficacy with improved safety profiles. Significance: Mesenchymal stem cells enable delivery of an oncolytic adenovirus specifically to the tumor without posing any risk associated with systemic administration of naked virions to the host. | en_US |
dc.description.sponsorship | This work was supported by grants from the National Research Foundation of Korea (2016M3A9B5942352 to C.-O. Yun; 2016R1C1B2015558 to A.-R. Yoon) and Korea Drug Development Fund (KDDF) funded by MSIP, MOTIE, and MOHW (KDDF-201611-05, Republic of Korea, to A.-R. Yoon). | en_US |
dc.language.iso | en | en_US |
dc.publisher | AMER ASSOC CANCER RESEARCH | en_US |
dc.subject | STROMAL CELLS | en_US |
dc.subject | CANCER | en_US |
dc.subject | SORAFENIB | en_US |
dc.subject | CAPACITY | en_US |
dc.subject | HYPOXIA | en_US |
dc.subject | PATHWAY | en_US |
dc.subject | SAFETY | en_US |
dc.subject | ALPHA | en_US |
dc.title | Mesenchymal Stem Cell-Mediated Delivery of an Oncolytic Adenovirus Enhances Antitumor Efficacy in Hepatocellular Carcinoma | en_US |
dc.type | Article | en_US |
dc.relation.no | 17 | - |
dc.relation.volume | 79 | - |
dc.identifier.doi | 10.1158/0008-5472.CAN-18-3900 | - |
dc.relation.page | 4503-4514 | - |
dc.relation.journal | CANCER RESEARCH | - |
dc.contributor.googleauthor | Yoon, A-Rum | - |
dc.contributor.googleauthor | Hong, JinWoo | - |
dc.contributor.googleauthor | Li, Yan | - |
dc.contributor.googleauthor | Shin, Ha Chul | - |
dc.contributor.googleauthor | Lee, Hyunah | - |
dc.contributor.googleauthor | Kim, Hyun Soo | - |
dc.contributor.googleauthor | Yun, Chae-Ok | - |
dc.relation.code | 2019001940 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF ENGINEERING[S] | - |
dc.sector.department | DEPARTMENT OF BIOENGINEERING | - |
dc.identifier.pid | chaeok | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.